Will immune checkpoint inhibitors become the new standard of care for urothelial cancer?
ESMO 2016: Press brief on results of CABOSUN trial cabozantinib compared to sunitinib in RCC
The resurgence of immunotherapy in the treatment of cancer
Cabozantinib for advanced renal cell carcinoma: the METEOR and CABOSUN trials
Patient selection is crucial for vaccine therapy success in kidney cancer